Leukemia

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.

Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

For Blood Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Certain oncology treatments can raise the risk of developing yet another cancer.

In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.

When a Guatemalan family faced cancer, they turned to the country where they had dual citizenship — and to each other — for help.

"If cancer wants to come after me again, it better be ready to fight!"

What are the odds that my friend, Michael, would be afflicted with the same rare disease that I had?

From celebrity news to a new partnership aimed to help patients and their caregivers, here’s what is making headlines in the cancer space this week.

Some of the greatest doctors in the world were responsible for my survival and recovery from acute myeloid leukemia…but the Three Stooges, W.C Fields, Abbott and Costello, Laurel and Hardy and The Marx Brothers played a major role as well.

Following its announcement of covering chimeric antigen receptor-T cell therapy nationwide, the Centers for Medicare and Medicaid Services has now made this highly-priced, but life-saving, treatment available to many who would not otherwise have access to it at their cancer centers.

Here are the top 5 CURE stories for July 2019.

Here is a list of the recent trial initiations that occurred within the cancer space in July.

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Children born to women who are considered severely obese have greater chances of developing cancer before the age of 5, according to new study findings.

From Trump’s executive order regarding drug prices to today’s top performers and athletes, here’s what is making headlines in the cancer space this week.

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia.

Here are the top 5 CURE stories for June 2019.

From cancer-sniffing dogs to music therapy for pain, here’s what is making headlines in the cancer space this week.